Some Lots of Tydemy Birth Control Pills Recalled Due to 'Reduced Effectiveness'
2023-08-02
WEDNESDAY, Aug. 2, 2023 -- Certain lots of the prescription birth control pill Tydemy may be less effective than expected, potentially resulting in an unintended pregnancy, because the pills do not contain enough of an active ingredient.
The U.S. Food and Drug Administration warned consumers about the issue Tuesday following a company announcement about the issue on July 29.
Two lots of Tydemy (drospirenone/ethinyl estradiol/levomefolate calcium) made by Lupin Pharmaceuticals do not contain the correct level of ascorbic acid, the FDA noted.
Lots L200183 and L201560, in 28-dose blister packs, were distributed throughout the United States between June 3, 2022, and May 31, 2023.
"To date, LupinLupin has received no reports of adverse events related to either recalled batches," the company noted. "Regardless, Lupin is recalling these two batches because if there were a significant reduction in the amount of inactive content (ascorbic acid), this could potentially impact the effectiveness of the product which could potentially result in unexpected pregnancy."
Patients should continue taking their medication, the FDA said, but they should also immediately contact their health care provider for advice about an alternative method of birth control.
The company had previously voluntarily recalled the two lots of Tydemy at the wholesale level.
"Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (866) 480-8206 Monday – Friday 9:00 a.m. to 5:00 p.m. EST," Lupin instructed in its statement. "For reimbursement, please have the recalled lots returned to Inmar Rx Solutions, Inc.; the lot number can be found on the side of the carton."
The FDA also encouraged health care providers and patients to report any adverse events or quality problems with this or other medications to the agency’s MedWatch Adverse Event Reporting program.
Sources
U.S. Food and Drug Administration, Aug. 1, 2023
Posted August 2023
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。